Duopharma Biotech Bhd
KLSE:DPHARMA
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Estee Lauder Companies Inc
NYSE:EL
|
Consumer products
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Church & Dwight Co Inc
NYSE:CHD
|
Consumer products
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
American Express Co
NYSE:AXP
|
Financial Services
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Target Corp
NYSE:TGT
|
Retail
|
| US |
|
Walt Disney Co
NYSE:DIS
|
Media
|
| US |
|
Mueller Industries Inc
NYSE:MLI
|
Machinery
|
| US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
Technology
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
1.13
1.4
|
| Price Target |
|
We'll email you a reminder when the closing price reaches MYR.
Choose the stock you wish to monitor with a price alert.
|
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
|
Estee Lauder Companies Inc
NYSE:EL
|
US |
|
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
|
Church & Dwight Co Inc
NYSE:CHD
|
US |
|
|
Pfizer Inc
NYSE:PFE
|
US |
|
|
American Express Co
NYSE:AXP
|
US |
|
|
Nike Inc
NYSE:NKE
|
US |
|
|
Visa Inc
NYSE:V
|
US |
|
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
|
3M Co
NYSE:MMM
|
US |
|
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
|
Coca-Cola Co
NYSE:KO
|
US |
|
|
Target Corp
NYSE:TGT
|
US |
|
|
Walt Disney Co
NYSE:DIS
|
US |
|
|
Mueller Industries Inc
NYSE:MLI
|
US |
|
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
This alert will be permanently deleted.
Duopharma Biotech Bhd
Revenue
Duopharma Biotech Bhd
Revenue Peer Comparison
Competitive Revenue Analysis
Latest Figures & CAGR of Competitors
| Company | Revenue | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
|
D
|
Duopharma Biotech Bhd
KLSE:DPHARMA
|
Revenue
myr748m
|
CAGR 3-Years
8%
|
CAGR 5-Years
7%
|
CAGR 10-Years
16%
|
|
P
|
PeterLabs Holdings Bhd
KLSE:PLABS
|
Revenue
myr181.7m
|
CAGR 3-Years
11%
|
CAGR 5-Years
14%
|
CAGR 10-Years
13%
|
|
A
|
Apex Healthcare Bhd
KLSE:AHEALTH
|
Revenue
myr962.2m
|
CAGR 3-Years
12%
|
CAGR 5-Years
8%
|
CAGR 10-Years
8%
|
|
R
|
Rhone Ma Holdings Bhd
KLSE:RHONEMA
|
Revenue
myr217.4m
|
CAGR 3-Years
11%
|
CAGR 5-Years
12%
|
CAGR 10-Years
N/A
|
|
Y
|
YSP Southeast Asia Holding Bhd
KLSE:YSPSAH
|
Revenue
myr364.5m
|
CAGR 3-Years
9%
|
CAGR 5-Years
4%
|
CAGR 10-Years
7%
|
|
K
|
Kotra Industries Bhd
KLSE:KOTRA
|
Revenue
myr226.6m
|
CAGR 3-Years
12%
|
CAGR 5-Years
6%
|
CAGR 10-Years
4%
|
See Also
What is Duopharma Biotech Bhd's Revenue?
Revenue
748m
MYR
Based on the financial report for Jun 30, 2024, Duopharma Biotech Bhd's Revenue amounts to 748m MYR.
What is Duopharma Biotech Bhd's Revenue growth rate?
Revenue CAGR 10Y
16%
Over the last year, the Revenue growth was 7%. The average annual Revenue growth rates for Duopharma Biotech Bhd have been 8% over the past three years , 7% over the past five years , and 16% over the past ten years .
You don't have any saved screeners yet
